Form 4: Poplar Point Capital Partners LP Increases Stake in NovaBay Pharmaceuticals

Poplar Point Capital Partners LP, along with related entities and Jad Fakhry, reports acquiring additional shares of NovaBay Pharmaceuticals common stock, increasing their holdings to over 800,000 shares.

Summary

• Poplar Point Capital Partners LP, Poplar Point Capital Management LLC, Poplar Point Capital GP LLC, and Jad Fakhry jointly filed a Form 4.
• The filing reports purchases of NovaBay Pharmaceuticals common stock between March 10, 2025, and March 18, 2025.
• The purchases were made at prices ranging from $0.58 to $0.635 per share.
• Following these transactions, the Reporting Persons beneficially own 818,277 shares of NovaBay Pharmaceuticals common stock.
• The Reporting Persons disclaim beneficial ownership of the securities covered by the statement other than the securities actually owned by such person.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The increased stake suggests confidence, but it's a routine filing.

Positives

• Increased investment by Poplar Point Capital Partners LP may signal confidence in NovaBay Pharmaceuticals.
• The purchases occurred at increasing prices, suggesting a positive outlook.

Management Comments

• The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders, providing transparency to the market.

Stakeholder Impact

• Shareholders may view the increased stake positively.
• The impact on other stakeholders is likely minimal.

Key Dates

Keywords

NovaBay Pharmaceuticals, Poplar Point Capital Partners, Form 4, Beneficial Ownership, Stock Acquisition, NBY, Jad Fakhry